Holding(s) in Company (0398I)

TIDMMDST

RNS Number : 0398I

Medicsight Plc

08 June 2011

 
 Press Release   8 June 2011 
 

Medicsight PLC

("Medicsight" or "the Company")

Notifiable Interest

The Company received the following notification on 7 June 2011:

 
 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 
------------------------------------------------ 
 
 
     1. Identity of the issuer or the underlying 
      issuer 
      of existing shares to which voting rights 
      are 
      attached:                                          Medicsight PLC 
------------------------------------------------  ---------------------------- 
  2. Reason for the notification (please tick the appropriate box 
   or boxes): 
------------------------------------------------------------------------------ 
  An acquisition or disposal of voting rights                            X 
--------------------------------------------------------------------  -------- 
  An acquisition or disposal of qualifying financial instruments 
   which may result in the acquisition of shares already 
   issued to which voting rights are attached 
--------------------------------------------------------------------  -------- 
  An acquisition or disposal of instruments with similar 
   economic effect to qualifying financial instruments 
--------------------------------------------------------------------  -------- 
  An event changing the breakdown of voting rights 
--------------------------------------------------------------------  -------- 
  Other (please specify): 
--------------------------------------------------------------------  -------- 
  3. Full name of person(s) subject 
   to the 
   notification obligation:                  MGT Capital Investments, Inc. 
---------------------------------------  ------------------------------------- 
  4. Full name of shareholder(s) 
   (if different from 3.): 
---------------------------------------  ------------------------------------- 
  5. Date of the transaction and 
   date on 
   which the threshold is crossed 
   or 
   reached:                                  6 June 2011 
---------------------------------------  ------------------------------------- 
  6. Date on which issuer notified:          7 June 2011 
---------------------------------------  ------------------------------------- 
  7. Threshold(s) that is/are crossed 
   or 
   reached:                                  55% to 53% 
---------------------------------------  ------------------------------------- 
 
 
 
 8. Notified details: 
 ----------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares 
------------------------------------------------------------------------------------------------ 
   Class/type 
    of shares 
    if possible   Situation previous 
    using the      to the triggering          Resulting situation after the triggering 
    ISIN CODE      transaction                 transaction 
---------------  ------------------------  ----------------------------------------------------- 
                                Number of    Number 
                  Number of     Voting       of         Number of voting        % of voting 
                  Shares        Rights       shares      rights                 rights 
 --------------  ----------  ------------  ---------- 
                                             Direct     Direct      Indirect   Direct   Indirect 
 --------------  ----------  ------------  ----------  ----------  ---------  -------  --------- 
   ordinary      86,000,000   86,000,000   83,910,000  83,910,000             53.94% 
---------------  ----------  ------------  ----------  ----------  ---------  -------  --------- 
 
 
 
 B: Qualifying Financial Instruments 
---------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------- 
    Type of                Expiration    Exercise/     Number of voting        % of 
  financial                 date         Conversion    rights that may be      voting 
 instrument                              Period        acquired if the         rights 
                                                       instrument is 
                                                       exercised/converted 
-----------  ------------------------  ------------  ---------------------  ------------ 
 
 
 
 C: Financial Instruments with similar economic effect to Qualifying 
  Financial Instruments 
--------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
--------------------------------------------------------------------------------------------- 
    Type of                Exercise    Expiration    Exercise/     Number of      % of voting 
  financial                 price       date         Conversion    voting          rights 
 instrument                                          period        rights 
                                                                   instrument 
                                                                   refers to 
-----------  ----------------------  ------------  ------------  ------------  -------------- 
                                                                               Nominal  Delta 
-----------  ----------------------  ------------  ------------  ------------  -------  ----- 
 
 
 
   Total (A+B+C) 
------------------------------------------------------------------ 
 Number of voting rights               % of voting rights 
------------------------------------  ---------------------------- 
   83,910,000                           53.94% 
------------------------------------  ---------------------------- 
  9. Chain of controlled undertakings through which the voting 
   rights and/or the financial instruments are effectively held, 
   if applicable: 
------------------------------------------------------------------ 
 
 
 
  Proxy Voting: 
------------------------------------------ 
         10. Name of the proxy holder: 
------------------------------------------ 
         11. Number of voting rights proxy 
          holder 
          will cease to hold: 
------------------------------------------ 
         12. Date on which proxy holder 
          will cease to 
          hold voting rights: 
------------------------------------------ 
 
 
         13. Additional information: 
---------------------------------------  ----------------- 
         14. Contact name:                 Robert Ladd 
---------------------------------------  ----------------- 
         15. Contact telephone number:     [phone] 
---------------------------------------  ----------------- 
 

- ENDS -

For further information:

 
 Medicsight plc 
 Allan Rowley, CEO   Tel: [phone] 
                           www.medicsight.com 
                         follow us on twitter 
                                  @Medicsight 
 
 
 Daniel Stewart & Co 
 Noelle Greenaway / Oliver Rigby   Tel: [phone] 
                                     www.danielstewart.co.uk 
 

Media enquiries:

 
 Abchurch 
                                       www.abchurch-group.com 
 Julian Bosdet                      Tel: [phone] 
 [e-mail] 
 Adam Michael                       Tel: [phone] 
 [e-mail] 
 Simone Elviss                      Tel: [phone] 
 [e-mail] 
 Quincy Allan                       Tel: [phone] 
 [e-mail] 
 

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been developed using a large and population diverse database of verified patient CT scan data. Medicsight's ColonCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) software uses an advanced CAD algorithm to analyse CT scans of the colon and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon.

ColonCAD can be seamlessly integrated with advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

About colorectal cancer

According to the American Cancer Society, colorectal cancer is one of the leading causes of cancer-related deaths in the United States with an estimated 49,000 colorectal cancer deaths expected during 2011. However regular screening (where polyps can be detected at an early stage before they have developed into cancer) is one of the most powerful methods of colorectal cancer prevention. Screening for colorectal polyps increases the probability of more colorectal cancers being detected earlier - when the disease is easier to cure.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLKDLFBFQFLBBQ